Myocardial Infarction
Conditions
Keywords
cell therapy, BMC, timing
Brief summary
Most studies on intracoronary bone marrow mononuclear cell (BMC) transplantation for acute myocardial infarction (AMI) involve treatment 3-7 days after primary percutaneous coronary intervention (PCI); however, the optimal timing is unknown. The present study assessed the therapeutic effect at different times after ST-elevation myocardial infarction (STEMI).
Detailed description
On the basis of experimental studies that bone marrow mononuclear cells (BMCs) transfer in the injured tissue can promote regional myocardial perfusion and improved cardiac function, several clinical trials have shown that intracoronary bone marrow mononuclear cell (BMC) transplantation in acute myocardial infarction (AMI) patients several days after myocardial reperfusion is safe and may enhance the improvement of left ventricular ejection fraction (LVEF). The timing of BMC administration, baseline LVEF, dosage of BMC and other factors has been linked to improvement in LVEF after BMC transplantation. In our previous work, we gave BMCs within 24 hours after emergency percutaneous coronary intervention (PCI) and found that it was safe and effective . In addition, there are another report about longer time from symptom onset to BMC infusion (2-4 weeks), which also appeared effective . The timing of intracoronary stem cell administration may have a critical effect on cell engraftment and may be responsible for the various biological and functional responses to therapy. However, few studies have directly addressed the optimal timing of cell injections. Therefore, in this prospective randomized study, BMCs were given at different times (within 24 hours, 3 to 7 days, or 7 to 30 days after reperfusion) to investigate whether the timing of therapy affects the therapeutic response of AMI patients.
Interventions
OTHERBMC therapy within 24 hours
The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
OTHERBMC therapy within 3-7 days
Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
OTHERBMC therapy within 7-30 days
Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
OTHERPCI only
The saline was intracoronary infusion with the use of microtubular.
Sponsors
Fudan University
The First Affiliated Hospital of Dalian Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* a history of first acute ST-elevation myocardial infarction * treatment with successful PCI two to twelve hours after symptom onset * LVEF less than 50% on angiography immediately after emergency PCI or rescue PCI
Exclusion criteria
* previous Q-wave myocardial infarction * cardiogenic shock * severe coexisting conditions such as acute and chronic heart failure, malignant * arrhythmia, renal failure and severe bleeding that interfered with the ability of the * patient to comply with the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of left ventricular eject factor (LVEF) from the baseline | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Change of left ventricular end-diastolic volume (LVESV) from the baseline | 12 months |
| Change of left ventricular end-systolic volume (LVEDV) from the baseline | 12 months |
| Change of myocardial perfusion from the baseline | 12 months |
Outcome results
None listed